Published in final edited form as:

Neurotox Res. 2017 November ; 32(4): 723–733. doi:10.1007/s12640-017-9776-z.

Human immunodeficiency virus promotes mitochondrial toxicity

Summer J. Rozzi¹, Valeria Avdoshina¹, Jerel A. Fields², Margarita Trejo², Hoai T. Ton³, Gerard P. Ahern³, and Italo Mocchetti¹

¹Laboratory of Preclinical Neurobiology, Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20057

²Departments of Psychiatry University of California San Diego, La Jolla, CA, USA

³Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20057

Abstract

Combined antiretroviral therapies (cART) have had remarkable success in reducing morbidity and mortality among patients infected with human immunodeficiency virus (HIV). However, mild forms of HIV-associated neurocognitive disorders (HAND), characterized by loss of synapses, remain. cART may maintain an undetectable HIV RNA load but does not eliminate the expression of viral proteins such as trans-activator of transcription (Tat) and the envelope glycoprotein gp120 in the brain. These two viral proteins are known to promote synaptic simplifications by several mechanisms, including alteration of mitochondrial function and dynamics. In this review, we aim to outline the many targets and pathways used by viral proteins to alter mitochondria dynamics, which contribute to HIV-induced neurotoxicity. A better understanding of these pathways is crucial for the development of adjunct therapies for HAND.

1. Introduction

Human immunodeficiency virus type-1 (HIV) infection continues to be a global health problem. In addition to infection and depletion of T cells, HIV rapidly enters the central nervous system (CNS) where it productively infects macrophages, microglia (Dunfee et al. 2006; Janssen et al. 1989), and to some extent astrocytes (Conant et al. 1994; Eugenin et al. 2011). The presence of the virus leads to progressive cognitive impairments in a large subset of infected individuals. Even with the advent and implementation of combined antiretroviral therapy (cART) to diminish HIV viral load, over 50% of HIV patients in the United States develop HIV-associated neurocognitive disorders (HAND) that range from asymptomatic to severe dementia (Clifford and Ances 2013; Nightingale et al. 2014). Behaviorally, HAND is characterized with executive dysfunction and memory impairments, with significant impairments in attention, multitasking, and judgment, as well as memory encoding and retrieval (Saylor et al. 2016). One of the hallmark neuropathological features most correlating with these cognitive deficits in HAND is synaptodendritic damage, particularly decreased synaptic and dendritic density (Ellis et al. 2007; Masliah et al. 1997). These

neuropathological indices are also confirmed in rodent models of HAND by showing significant neuronal atrophy accompanied by disruption to neuronal function (Bachis et al. 2016; D'Hooge et al. 1999; Toggas et al. 1994). However, the mechanisms by which HIV damages the CNS remain obfuscated considering that microglia but not neurons are infected.

Postmortem brains of HIV-positive individuals with cognitive alterations exhibit signs of impaired mitochondrial metabolism (Bennett et al. 2014; Opii et al. 2007). In addition, when compared to HIV positive with no cognitive alterations, HAND brains contain mitochondria with abnormal morphology (Avdoshina et al. 2016a; Fields et al. 2016), including the lack of integrity of inner membrane cristae (Fig. 1). This scenario is similar to that observed in other neurological diseases such as Alzheimer's disease in which mitochondrial ultrastructure is altered in such a way that cristae are disrupted (Reddy and Reddy 2011). Mitochondria play a role in neuronal survival through a variety of metabolic mechanisms (Mattson et al. 2008), Ca^{2+} homeostasis and the reduction of reactive oxygen species (ROS), among them. In addition, mitochondria control the production of high-energy intermediates, such as ATP. Neurons are highly energetically dependent and require ATP at distant regions such as axonal and dendritic synapses, linking their function and survival tightly with ATP production (Berthet et al. 2014; Dickey and Strack 2011; Merrill et al. 2011). Thus, it is not surprising that mitochondrial dysfunction and disruption of energy production have been proposed to cause neurodegenerative diseases (Burte et al. 2015). The question remains as to how HIV promotes mitochondrial impairment.

2. Viral proteins

All HIV-mediated neuronal complications are the consequences of immune activation, oxidative stress, and neurotoxicity that result from either persistent HIV replication in the brain or the release of viral proteins, such as Tat, gp120, and Nef. These proteins are directly toxic to neurons by a variety of mechanisms. In this review, we will be focused on Tat and gp120, as the most neurotoxic viral proteins that promote neuronal injury by altering mitochondrial dynamics.

2.1 Tat

HIV Tat, a trans-activator of transcription for viral replication, is produced by infected cells once the proviral DNA is formed, and is released from infected lymphoid (Ensoli et al. 1993), monocytic cells (Turchan et al. 2001), and glial cells (Tardieu et al. 1992). Additionally, Tat has been detected in the brains of patients with HIV encephalitis by immunostaining (Del Valle et al. 2000; Hudson et al. 2000) or in the cerebrospinal fluid (CSF) by a sensitive ELISA (Bachani et al. 2013). Thus, Tat expression in the CNS persists despite cART. The expression of Tat is consistent with the view that the brain is a reservoir for HIV.

Tat is one of the HIV proteins with potent neurotoxic activity and various mechanisms of neurotoxicity. Tat induces DNA double strand breaks (Rozzi et al. 2014). This Tat property could be arising from its function as viral transcriptional regulator in the nucleus (Liu et al. 2000; Stauber and Pavlakis 1998). Unrepaired DNA double strand breaks are lethal to cells (Mehta and Haber 2014). Moreover, Tat is also transported along axons and promotes

toxicity upon distal sites by traveling through anatomical pathways (Bruce-Keller et al. 2003). However, many of the neurotoxic effects of Tat appear to be mediated by its interactions with cell membrane receptors including the N-methyl-D-Aspartate (NMDA) subtype of glutamate receptors (Eugenin et al. 2007; Haughey et al. 2001; Li et al. 2008). Tat-mediated neuronal injury can be seen at several levels including synaptic and dendritic pruning (Kim et al. 2008), induction of apoptotic cascades (Aksenova et al. 2009), Ca^{2+} dysregulation (Self et al. 2004), and oxidative stress (Aksenov et al. 2003). These neurotoxic effects are not cell specific because in addition to NMDA positive neurons, are seen in other neuronal populations, including dopaminergic neurons (Bennett et al. 1995; Ferris et al. 2010; Moran et al. 2013).

2.2. Gp120

Glycoprotein 120 (gp120) is a part of the viral envelope that is essential for viral infection. It facilitates HIV entry into the host cell by binding to CD4 and the chemokine co-receptors CCR5 and CXCR4 (Deng et al. 1996). Indeed, antagonists of these receptors inhibit HIV infection (Scarlatti et al. 1997).

Much like Tat, the neurotoxic mechanisms attributed to gp120 are multiple. Neurons do not express CD4, but express both CCR5 and CXCR4. It is widely recognized that gp120, through chemokine receptors, is a potent neurotoxin, promoting neuronal injury *in vitro* in the picomolar range (Bachis et al. 2003; Lipton et al. 1991; Meucci and Miller 1996). Moreover, mice genetically expressing gp120 (gp120tg) exhibit neuropathological features observed in HAND, such as retracted neuronal processes (Toggas et al. 1994) and loss of dendritic spines (Bachis et al., 2016).

Gp120, after binding to chemokine receptors, activates apoptotic pathways that lead to neuronal dysfunction and loss (Kaul et al. 2001). Such pathways include dysregulation of Ca^{2+} homeostasis (Haughey and Mattson 2002), activation of oxidative stress (Mattson et al. 2005), and induction of the proapoptotic transcription factor p53 (Garden et al. 2004). In addition, there are indirect mechanisms that may account for gp120 neurotoxicity. For instance, gp120 enhances blood-brain barrier permeability (Cioni and Annunziata 2002) by acting through down-regulation of tight junction proteins, such as zonula occludens (ZO)-1, ZO-2 and occludin (Kanmogne et al. 2005). Gp120 also enhances the expression of matrix metalloproteases 2 and 9, which increase permeability of brain endothelial cells (Price et al. 2005; Price et al. 2006) and lipid peroxidation in neurons as well as in the vascular endothelium (Louboutin et al. 2010). These changes increased the trafficking of toxic humoral factors, which may contribute to the pathogenesis of HAND.

3. Viral proteins and Mitochondria

3.1. Tat and gp120 change mitochondrial dynamics

HIV promotes mitochondrial-mediated apoptosis of T cells (Grimaldi et al. 2005; Matarrese et al. 2003). However, the discovery that the function (Lehmann et al. 2011; Zhang et al. 2012) and morphology of neuronal mitochondria in HAND subjects are altered (Avdoshina et al. 2016a; Fields et al. 2016) expanded the interest in mitochondrial research in the

neuroAIDS field as a possible explanation for causes of neuronal degeneration. Because mislocalization of mitochondria and perturbations to energy production are known to impair neuronal function, and have been linked to neurodegenerative diseases (Burte et al. 2015), we will review some of the overwhelming evidence that points at impaired mitochondrial dynamics/function as an important contributor for HIV-induced neurotoxicity.

Tat and gp120 appear to exert a differential effect on mitochondria, which can be equally deleterious. Tat exposure causes a biphasic increase in mitochondrial membrane potential that is both concentration- and time-dependent (Norman et al. 2007). This increase is linked to significant alterations in synaptic activity, which was surprisingly not found to be due to disruption to mitochondrial distribution, localization, or morphology. Gp120, in contrast, progressively decreased mitochondrial membrane potential (over a time period of 6 h) by mechanisms that could involve excessive release of Ca^{2+} from endoplasmic reticulum, by activation of voltage dependent Ca^{2+} channels (Haughey and Mattson 2002) or increased NMDA trafficking (Xu et al. 2011).

3.2. Mitochondria morphology

Important aspects of mitochondria functionality are organelle biogenesis and morphology. These occurrences are regulated through mitochondrial fusion and fission (Westermann 2010), which allow mitochondria to fuse together, becoming elongated, or convert into large number of small fragments, respectively. The main mitochondrial fission and fusion proteins are members of the dynamin family, which includes mitofusins (Mfn1-2), dynamin-related protein 1 (Drp1) and optic atrophy 1 (Opa1), each one with a GTPase domain (van der Bliek et al. 2013). Tat and gp120 appear to change the levels and function of some of these proteins, and consequently affect the morphology and number of mitochondria. For instance, the ability of gp120 to increase Mfn1 and Opa1 (Fields et al. 2016) could explain why mitochondria are elongated in neurons exposed to gp120 both *in vitro* (Avdoshina et al. 2016a). Changes in mitochondrial morphology by gp120 are not an *in vitro* artifact because the cortex of mice expressing gp120 (gp120-tg) under a glial fibrillary acidic protein promoter (Toggas et al. 1994), exhibit elongated mitochondria with broken cristae (Fig. 2). These mice, which display impaired cognitive behavior and pathological features similar to HAND (Toggas et al. 1994), are considered a valid animal model to study the molecular and cellular mechanisms of HIV neurotoxicity. Thus, it should not be surprising that the loss of mitochondrial cristae detected in these mice (Fig. 2) is similar to that observed in HAND (Fig. 1). Moreover, gp120 decreases Fis-1, a mitochondrial outer membrane protein that regulates mitochondrial fission. Down regulation of Fis-1 can lead to progressive elongated mitochondria (Stojanovski et al. 2004) accompanied by early senescence (Yoon et al. 2006). Tat, on the other hand, reduces the size of neuronal mitochondria by a mechanism that appears to either interfere with fusion of damaged mitochondria with healthy one, or to increase fission and inhibit the elimination of damage mitochondria by mitophagy (Rozzi, unpublished). Regardless of which mechanisms are utilized by viral proteins, it is plausible that HIV is neurotoxic by acting on proteins that are important for mitochondrial number and morphology.

3.3. HIV proteins and ATP

One of the main functions of mitochondria is to synthesize ATP from dietary sugar or amino acids by ATP-synthase in the electron transport chains (ETC). The ATP produced relies upon an intact and efficient ETC, the activity of four key proteins that make up the redox carrier, named complex I–IV, and the surface area of cristae (Demongeot et al. 2007). The mitochondrial membrane potential (Ψ_m) is also critical for the generation of ATP and loss of Ψ_m leads to ATP depletion within the cell thereby contributing to neuronal death (Joshi and Bakowska 2011). Neurons are highly-energetically dependent cells as they require as much as 10^4 ATP molecules to transmit a bit at a chemical synapse (Laughlin et al. 1998). Thus, impairment at any step of the ETC or malformed cristae, similar to that described in HIV positive subjects (Avdoshina et al. 2016a), could lead to loss of ATP and the formation of superoxide free-radicals. For instance, primary cerebrocortical cells exposed to gp120 exhibit a significant loss of neuronal ATP (Sanchez et al. 2015). This effect could be due to the ability of gp120 to decrease the area of cristae, to block mitochondrial movements, or to increase mitochondrial fusion and thereby inhibit mitophagy (Avdoshina et al. 2016a).

The effect of Tat upon ATP production has conflicting data (Perry et al. 2005; Tiede et al. 2011; Villeneuve et al. 2016), with indications of both increases and decreases in ATP production, in all instances preceding cell death. Nevertheless, the ability of Tat to cause a drastic inhibition of ATP synthase (Lecoeur et al. 2012; Norman et al. 2007) points to a disruption of mitochondrial function. Changes in ETC protein function lead to rapid dissipation of the mitochondrial membrane potential, inhibition of mitochondrial calcium uptake, and release of cytochrome c, a water-soluble component of ETC located within the inner membrane of mitochondria. The release of cytochrome c is a strong indication that apoptosis is activated. Indeed, mitochondria are also involved in the cytochrome c or caspase-dependent death pathway (Garrido et al. 2006; Liu et al. 1996). In contrast, gp120 has been shown to affect both cytochrome c dependent (Garden et al. 2002) and independent apoptosis (Singh et al. 2004). It is important to note that these findings were obtained in cortical and striatal cultures, respectively, suggesting that gp120 may activate different mechanisms of apoptosis depending upon cell types. Regardless of whether Tat and gp120 decrease ATP formation, when Tat or gp120-mediated mitochondrial membrane potential changes are blocked, neurons can be spared from undergoing apoptosis (Lecoeur et al. 2012; Turchan et al. 2001). This consideration indicates that the integrity of mitochondrial function is key to explain the neurotoxic properties of Tat and gp120 and that keeping this function intact could be a therapeutic target to improve neuronal survival following HIV infection.

4. Mitochondrial-dependent apoptosis and Ca^{2+} dysregulation

Mitochondria are essential for buffering intracellular (or cytosolic) free calcium ($[\text{Ca}^{2+}]_i$), preventing abnormal elevations in $[\text{Ca}^{2+}]_i$ that otherwise would promote a bioenergetic failure of the organelle. High concentrations of Ca^{2+} (and other ions) promote the opening of the permeability transition pore (PTP) located on the mitochondria inner membranes (Bernardi et al. 2015). Prolonged or persistent PTP opening causes mitochondrial depolarization and release of cytochrome c from the mitochondrial intermembrane space. Cytochrome c is required for the activation of the initiator of apoptosis, caspase-9, by

forming the apoptosomic complex with Apaf-1 (Li et al. 2017). Such complex activates the effector caspase-3 and triggers a feedback loop for mitochondrial disruption through cleavage of anti-apoptotic Bcl-2 family proteins (Chen et al. 2007).

Several HIV proteins have been found to activate key components of PTP opening. Most clearly delineated is the HIV regulatory protein Vpr, which ensures the replication of HIV in infected cells (Schuler et al. 1999). Vpr has been shown to directly target the PTP complex, allowing for the permeabilization of mitochondrial membranes (Jacotot et al. 2000). Additionally, Tat may cause the translocation of Bim, a member of the pro-apoptotic Bcl-2 family, from microtubules to mitochondria, where it induces PTP (Chen et al. 2002). The acute calcium overload caused by Tat can also trigger PTP complex formation. In more recent investigations, Tat was found to have no effect upon Bcl-2 and neither Bax-inhibiting peptide nor Bax channel inhibitor could alter Tat-induced cytochrome c release (Lecoeur et al. 2012). Taken together, these data suggest Tat-induced PTP might be independent of the canonic Bax/Bak mediated mitochondrial PTP pathway.

Another toxic effect of $[Ca^{2+}]_i$ is the activation of nitric oxide synthase (NOS). This enzyme, which catalyzes the formation of NO from L-arginine, can be expressed in neurons (nNOS, or NOS-1) as well as by activated microglia (iNOS or NOS-2). Increases in NO can react with cellular superoxide forming the damaging peroxynitrite and promote several forms of neurodegenerative diseases (Boje 2004). Tat affects both iNOS (Polazzi et al. 1999) as well as nNOS (Eugenin et al. 2007) by increasing $[Ca^{2+}]_i$ through release of intracellular stores (Krogh et al. 2014; Kruman et al. 1998) as well as through the Ca^{2+} influx obtained by activation of NMDA receptors (Haughey et al. 2001). The toxic effects of Tat-induced increases in $[Ca^{2+}]_i$ are mitigated by Ca^{2+} chelators as well as inhibitors of mitochondria Ca^{2+} uptake (Kruman et al. 1998), supporting the role of $[Ca^{2+}]_i$ dysregulation in Tat neurotoxicity.

In addition to plasma membrane Ca^{2+} channels, eukaryotic cells control Ca^{2+} homeostasis by Ca^{2+} channels located on endoplasmic reticulum (ER), mitochondria and other organelles, Ca^{2+} buffering proteins, and systems for Ca^{2+} extrusion and sequestration (Contreras et al. 2010). Thus, it is important to consider that Tat may also affect Ca^{2+} homeostasis in a NMDA receptor-independent manner. Indeed, Tat has been shown to deplete both mitochondrial Ca^{2+} (Norman et al. 2007) as well as ER Ca^{2+} by activation of ryanodine receptors (Norman et al. 2008). Moreover, Tat appears to increase $[Ca^{2+}]_i$ by activation of L-type channels (Hu 2016). Our preliminary data presented in Fig. 3 support the view that Tat can also affect cytosolic Ca^{2+} in an NMDA-independent manner. In fact, MK801, a selective non-competitive NMDA receptor antagonist, failed to block Tat-mediated increase in $[Ca^{2+}]_i$ in cortical neurons *in vitro* (Fig. 3). This is in spite of the fact that the NMDA-mediated rise in $[Ca^{2+}]_i$ was prevented by the concurrent administration of MK801 (Fig. 3). Thus, it appears that Tat perturbs Ca^{2+} homeostasis by affecting both ER and other organelles controlling Ca^{2+} as well as Ca^{2+} regulating systems located in plasma membrane (Haughey et al. 2001). Irrespective of the ultimate mechanisms, all evidence points at altered Ca^{2+} homeostasis as one of the main mechanisms of Tat neurotoxicity (Haughey and Mattson 2002).

Gp120 appears to modulate $[Ca^{2+}]_i$ by a different mechanism. In fact, in contrast to Tat, gp120 increases $[Ca^{2+}]_i$ mostly by the mobilization of inositol triphosphate (IP_3)-sensitive calcium pools (Nath et al. 2000; Pandey and Bolsover 2000). This is supported by the data showing that inhibition of IP_3 -sensitive but not ryanodine-sensitive ER calcium stores reduced gp120-evoked increases of Ca^{2+} (Hoke et al. 2009). Nevertheless, pathological consequences of a direct modification of ER Ca^{2+} stores is deleterious, exemplified by prominent dilation of the ER as well as enlarged mitochondria both in rodents and postmortem human brains (Norman et al. 2008).

As viral protein-induced mitochondrial toxicity has been repeatedly linked to disruption of Ca^{2+} homeostasis, it comes as no surprise that indirect ways to prevent Tat or gp120 toxicity include a blockade of receptor-mediated Ca^{2+} influx. This includes reduction of NMDA receptor activation by mild receptor antagonists, such as Memantine, which has also been shown to protect neuronal function against gp120-mediated toxicity (Anderson et al. 2004; Nath et al. 2000).

5. Mitochondria transport

Many recent investigations have identified disruption of mitochondrial dynamics and resulting neuronal dysregulation as mechanisms contributing to the toxicity observed in neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's Diseases (Mattson et al. 2008). Studies are beginning to identify mitochondrial abnormalities as causative factors for the neuropathology observed in HAND (Avdoshina et al. 2016a; Fields et al. 2016). The evidence for viral protein-induced mitochondrial impairment in neurons is plentiful, however many questions remain as to which mechanism(s) account for the abnormal mitochondria morphology/number in HAND.

Disruption of mitochondrial membrane potential, altered ATP production, and release of ROS can all be modulated through the dynamic processes of mitochondrial fusion and fission (Burte et al. 2015). Mitochondria are then transported to different cellular locations such as axons and dendrites, where ATP is in high demand. The proper intracellular distribution of mitochondria is essential for the maturation of dendritic spines (Li et al. 2004) and support of synaptic plasticity (Todorova and Blokland 2017). In addition, damaged and dysfunctional mitochondria are retrogradely transported to the soma to be repaired.

Recently, Avdoshina et al., proposed a novel mechanism of HIV neurotoxicity that depends upon disrupted mitochondrial dynamics. The mechanism is based on the ability of gp120 to directly bind neuron-specific tubulin β -3 (Avdoshina et al. 2016b), a component of neuronal microtubules that plays a crucial role in anterograde and retrograde neuronal transport including mitochondria. The inhibition of this transport, as proposed for gp120, results in accumulation of damaged mitochondria in the synapses (Fig. 2) and elongated mitochondria in the soma (Avdoshina et al. 2016a). Thus, these mitochondria cannot deliver a continuous supply of ATP to axonal or dendritic terminals. Live imaging data of rodent neurons confirmed that gp120 elicits a profound impairment of mitochondrial trafficking to the point where mitochondria stop their bidirectional movement and alters fusion and fission

(Avdoshina et al. 2016a). Defective mitochondrial transport has been suggested to cause synaptic injury in some neurodegenerative diseases (Burte et al. 2015; Itoh et al. 2013). Thus, impaired mitochondrial trafficking by gp120 could be one of the key pathogenic mechanisms to explain how HIV produces synaptic simplification and neuronal degeneration. Moreover, impaired trafficking in neurons can also contribute to depletion of neurotrophic support, and consequently reduce the number of synapses (Avdoshina et al. 2013).

The accumulation of impaired mitochondria can also have a significant impact on the health of neurons. Under normal circumstances, defective mitochondria will be disposed of through the mitochondria specific process of mitophagy (Sheng 2014). Tat and gp120 may promote abnormal neuronal autophagy and degradation of critical intracellular components (Fields et al. 2015). Tat is known to increase the instance of association of Parkin-ring-like structures to the surface of injured mitochondria; however, it does not increase autophagic flux (De Simone et al. 2016). In another study with implications for mitophagy function, Tat induces disruption of the endolysosomal and autophagy pathways. These mechanisms are particularly important for mitochondrial health, since dysfunctional lysosomes could preclude homeostatic autophagy and mitophagy processes (Hui et al. 2012). As we know from investigations of other neurodegenerative diseases, these alterations in autophagy can be detrimental to neuronal function and survival. Further investigation into the direct impact of altered mitophagic flux will be important for understanding the implications in HAND.

6. Preventing HIV-induced mitochondrial toxicity

No current therapy can target HIV proteins, allowing them to perpetuate their toxicity throughout the CNS. However, *in vitro* or *in vivo* investigations have identified potential therapeutic avenues that can mitigate the effects of viral protein-induced mitochondrial toxicity. Antioxidants, including Trolox, Cu/Zn SOD1, GPx1, and PACAP27 have been found in multiple *in vitro* experimental approaches to reduce Tat- and gp120 induced oxidative stress and prevent neuronal apoptosis (Agrawal et al. 2006; Agrawal et al. 2012; Butler et al. 2011; Pocernich et al. 2005; Rozzi et al. 2014). Ascorbate supplementation (ascorbate-2-O-phosphate) prevents the deleterious upregulation of iNOS and associated neuronal injury caused by gp120 in brain cell cultures (Walsh et al. 2004). Creatine is protective against Tat-induced ATP depletion, mitochondria membrane potential reduction, ROS production, and synapse loss (Stevens et al. 2014). Further, prevention of Tat endocytosis by heparan sulfate and dextran sulfate mitigated its mitochondrial neurotoxicity (Chauhan et al. 2003). Similarly, epicatechin, a flavonoid contained in food such as chocolate and green tea, has also been found to reduce Tat-mediated mitochondrial toxicity in cultured neurons (Nath et al. 2012), likely through the increase of the neurotrophin brain-derived neurotrophic factor (BDNF). This neurotrophin has a potent and widespread neuroprotective activity against several neurotoxins including gp120 (Bachis et al. 2003). Intriguingly, BDNF also prevents gp120-mediated neuronal apoptosis by decreasing the expression of the chemokine receptor CXCR4 (Bachis et al. 2003). In addition, BDNF has been known to induce mitochondrial biogenesis in newly generated neurons (Cheng et al. 2012), and to stimulate brain mitochondrial metabolism by increasing the efficiency of respiratory coupling and ATP synthesis (Marosi and Mattson 2014). Recently, BDNF has

been shown to regulate mitochondrial transport and distribution in neurons promoting the docking of the organelles at sites of synaptic transmission, thereby facilitating neurotransmission (Su et al. 2014). Thus, it is plausible that BDNF is neuroprotective against HIV because it restores the proper mitochondrial function that is impaired by Tat and gp120.

Adding to the complexity of Ca^{2+} influx in Tat or gp120-mediated neurodegeneration is the fact that both these viral proteins can kill neurons by a non-cell-autonomous mechanism. For example, the neurotrophin receptor p75NTR, a member of tumor necrosis factor of receptors, has been shown to promote apoptosis (Bredesen and Rabizadeh 1997) and axonal degeneration (Singh et al. 2008). This receptor induces long-term depression through Ca^{2+} influx (Woo et al. 2005). Gp120 indirectly activates p75NTR by increasing the levels of the BDNF precursor protein, proBDNF (Bachis et al. 2012), which, in turn, causes loss of dendritic spines (Bachis et al. 2016) and negatively influences other forms of synaptic plasticity (Yang et al. 2014). Small molecules like LM11A-31, which inhibit p75NTR (Pehar et al. 2006), or blocking antibodies against p75NTR (Bachis et al. 2012) are able to protect neurons from HIV-induced toxicity either by blocking calcium accumulation (Williams et al. 2016), or reducing p75NTR-mediated activation of pro-apoptotic signal (Bachis et al. 2012). A clear challenge in the field is to validate the data obtained in animal models to HAND subjects. Nevertheless, animal and human studies of HAND samples have confirmed that proBDNF levels are up-regulated and are a primary cause of neuronal loss (Bachis et al. 2012).

7. Conclusion

Due to the efficacy of antiretroviral therapies, the population of HIV infected individuals continues to age (Saylor et al. 2016). In 2013, people aged 55 and older accounted for more than one quarter of the estimated 1.2 million people living with diagnosed or undiagnosed HIV in the United States. While this expanded lifespan is wholly a good thing for the patient population, it comes with an added layer of complexity in terms of the neurocognitive impairments observed in the same population. Some aging paradigms feature mitochondria and numerous studies find mitochondrial changes occur with normal aging (Balaban et al. 2005; Gadaleta et al. 1998; Mattson et al. 2008). Combined with the neurotoxic effects of HIV proteins such as Tat and gp120, the neurocognitive impairments observed in these patients are likely to increase in incidence and severity. Continued exploration of the combined effects of aging and HIV proteins will be important to uncover mechanisms at play and to develop therapies to combat such neuronal disruptions.

Decades of research have identified numerous mechanisms of toxicity by which HIV, through viral proteins, impairs neuronal function and health, contributing the cognitive impairments observed in HAND. Nevertheless, therapies specifically targeting the neuronal degeneration seen in HAND are still unavailable, mostly due to an incomplete understanding of all mechanisms used by viral proteins to promote neurodegeneration. The viral protein-induced mitochondrial impairment is one crucial aspect of HIV neurotoxicity. Further investigation into the direct effects of Tat and gp120 upon mitochondria and their dynamic

processes will strengthen the field and likely enable the development of beneficial treatments for those with HAND in the future.

Acknowledgments

This work was supported by HHS grants 1R01 NS079172 to I.M. and T32 NS041218 to S.R.

References

- Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. *Gene Ther.* 2006; 13:1645–1656. DOI: 10.1038/sj.gt.3302821 [PubMed: 16871233]
- Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. *Neurobiol Dis.* 2012; 45:657–670. DOI: 10.1016/j.nbd.2011.10.005 [PubMed: 22036626]
- Aksenov MY, Hasselrot U, Wu G, Nath A, Anderson C, Mactutus CF, Booze RM. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrogliosis, and protein oxidation in the rat striatum. *Brain Res.* 2003; 987:1–9. [PubMed: 14499939]
- Aksenova MV, Aksenov MY, Adams SM, Mactutus CF, Booze RM. Neuronal survival and resistance to HIV-1 Tat toxicity in the primary culture of rat fetal neurons. *Exp Neurol.* 2009; 215:253–263. DOI: 10.1016/j.expneurol.2008.10.006 [PubMed: 19013459]
- Anderson ER, Gendelman HE, Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. *J Neurosci.* 2004; 24:7194–7198. DOI: 10.1523/JNEUROSCI.1933-04.2004 [PubMed: 15306653]
- Avdoshina V, Bachis A, Mocchetti I. Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity? *J Intern Med.* 2013; 273:454–465. DOI: 10.1111/joim.12050 [PubMed: 23600400]
- Avdoshina V, Fields JA, Castellano P, Dedoni S, Palchik G, Trejo M, Adame A, Rockenstein E, Eugenin E, Masliah E, Mocchetti I. The HIV protein gp120 alters mitochondrial dynamics in neurons. *Neurotox Res.* 2016a; 29:583–593. [PubMed: 26936603]
- Avdoshina V, Taraballi F, Dedoni S, Corbo C, Paige M, Saygideger Kont Y, Uren A, Tasciotti E, Mocchetti I. Identification of a binding site of the human immunodeficiency virus envelope protein gp120 to neuronal-specific tubulin. *J Neurochem.* 2016b; 137:287–298. DOI: 10.1111/jnc.13557 [PubMed: 26826352]
- Bachani M, Sacktor N, McArthur JC, Nath A, Rumbaugh J. Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders. *J Neurovirol.* 2013; 19:82–88. DOI: 10.1007/s13365-012-0144-8 [PubMed: 23329164]
- Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. *J Neurosci.* 2012; 32:9477–9484. DOI: 10.1523/JNEUROSCI.0865-12.2012 [PubMed: 22787033]
- Bachis A, Major EO, Mocchetti I. Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. *J Neurosci.* 2003; 23:5715–5722. [PubMed: 12843275]
- Bachis A, Wenzel E, Boelk A, Becker J, Mocchetti I. The neurotrophin receptor p75 mediates gp120-induced loss of synaptic spines in aging mice. *Neurobiol Aging.* 2016; 46:160–168. DOI: 10.1016/j.neurobiolaging.2016.07.001 [PubMed: 27498053]
- Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. *Cell.* 2005; 120:483–495. DOI: 10.1016/j.cell.2005.02.001 [PubMed: 15734681]
- Bennett BA, Rusyniak DE, Hollingsworth CK. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. *Brain Res.* 1995; 705:168–176. [PubMed: 8821747]
- Bennett GJ, Doyle T, Salvemini D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. *Nat Rev Neurol.* 2014; 10:326–336. DOI: 10.1038/nrneurol.2014.77 [PubMed: 24840972]

- Bernardi P, Rasola A, Forte M, Lippe G. The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology. *Physiol Rev*. 2015; 95:1111–1155. DOI: 10.1152/physrev.00001.2015 [PubMed: 26269524]
- Berthet A, Margolis EB, Zhang J, Hsieh I, Zhang J, Hnasko TS, Ahmad J, Edwards RH, Sesaki H, Huang EJ, Nakamura K. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. *J Neurosci*. 2014; 34:14304–14317. DOI: 10.1523/JNEUROSCI.0930-14.2014 [PubMed: 25339743]
- Boje KM. Nitric oxide neurotoxicity in neurodegenerative diseases. *Front Biosci*. 2004; 9:763–776. [PubMed: 14766406]
- Bredesen DE, Rabizadeh S. p75NTR and apoptosis: Trk-dependent and Trk-independent effects. *Trends Neurosci*. 1997; 20:287–290. [PubMed: 9223218]
- Bruce-Keller AJ, Chauhan A, Dimayuga FO, Gee J, Keller JN, Nath A. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. *J Neurosci*. 2003; 23:8417–8422. [PubMed: 12968004]
- Burte F, Carelli V, Chinnery PF, Yu-Wai-Man P. Disturbed mitochondrial dynamics and neurodegenerative disorders. *Nat Rev Neurol*. 2015; 11:11–24. DOI: 10.1038/nrneurol.2014.228 [PubMed: 25486875]
- Butler TR, Smith KJ, Self RL, Braden BB, Prendergast MA. Neurodegenerative effects of recombinant HIV-1 Tat(1-86) are associated with inhibition of microtubule formation and oxidative stress-related reductions in microtubule-associated protein-2(a,b). *Neurochem Res*. 2011; 36:819–828. DOI: 10.1007/s11064-011-0409-2 [PubMed: 21259049]
- Chauhan A, Turchan J, Pocernich C, Bruce-Keller A, Roth S, Butterfield DA, Major EO, Nath A. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. *J Biol Chem*. 2003; 278:13512–13519. DOI: 10.1074/jbc.M209381200 [PubMed: 12551932]
- Chen D, Wang M, Zhou S, Zhou Q. HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. *EMBO J*. 2002; 21:6801–6810. [PubMed: 12486001]
- Chen M, Guerrero AD, Huang L, Shabier Z, Pan M, Tan TH, Wang J. Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. *J Biol Chem*. 2007; 282:33888–33895. DOI: 10.1074/jbc.M702969200 [PubMed: 17893147]
- Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, Luo Y, Okun E, Mattson MP. Involvement of PGC-1 α in the formation and maintenance of neuronal dendritic spines. *Nat Commun*. 2012; 3:1250.doi: 10.1038/ncomms2238 [PubMed: 23212379]
- Cioni C, Annunziata P. Circulating gp120 alters the blood-brain barrier permeability in HIV-1 gp120 transgenic mice. *Neurosci Lett*. 2002; 330:299–301. [PubMed: 12270651]
- Clifford DB, Ances BM. HIV-associated neurocognitive disorder. *Lancet Infect Dis*. 2013; 13:976–986. DOI: 10.1016/S1473-3099(13)70269-X [PubMed: 24156898]
- Conant K, Tornatore C, Atwood W, Meyers K, Traub R, Major EO. *In vivo* and *in vitro* infection of the astrocyte by HIV-1. *Adv Neuroimmunol*. 1994; 4:287–289. [PubMed: 7874397]
- Contreras L, Drago I, Zampese E, Pozzan T. Mitochondria: the calcium connection. *Biochim Biophys Acta*. 2010; 1797:607–618. DOI: 10.1016/j.bbabi.2010.05.005 [PubMed: 20470749]
- D'Hooge R, Franck F, Mucke L, De Deyn PP. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. *Eur J Neurosci*. 1999; 11:4398–4402. [PubMed: 10594667]
- De Simone FI, Darbinian N, Amini S, Muniswamy M, White MK, Elrod JW, Datta PK, Langford D, Khalili K. HIV-1 Tat and Cocaine Impair Survival of Cultured Primary Neuronal Cells via a Mitochondrial Pathway. *J Neuroimmune Pharmacol*. 2016; 11:358–368. DOI: 10.1007/s11481-016-9669-6 [PubMed: 27032771]
- Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. *J Neurovirol*. 2000; 6:221–228. [PubMed: 10878711]

- Demongeot J, Glade N, Hansen O, Moreira A. An open issue: the inner mitochondrial membrane (IMM) as a free boundary problem. *Biochimie*. 2007; 89:1049–1057. DOI: 10.1016/j.biochi.2007.04.009 [PubMed: 17560004]
- Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. *Nature*. 1996; 381:661–666. [PubMed: 8649511]
- Dickey AS, Strack S. PKA/AKAP1 and PP2A/Bbeta2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. *J Neurosci*. 2011; 31:15716–15726. DOI: 10.1523/JNEUROSCI.3159-11.2011 [PubMed: 22049414]
- Dunfee R, Thomas ER, Gorrry PR, Wang J, Ancuta P, Gabuzda D. Mechanisms of HIV-1 neurotropism. *Curr HIV Res*. 2006; 4:267–278. [PubMed: 16842080]
- Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. *Nat Rev Neurosci*. 2007; 8:33–44. [PubMed: 17180161]
- Ensign B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. *J Virol*. 1993; 67:277–287. [PubMed: 8416373]
- Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. *J Neurosci*. 2011; 31:9456–9465. 31/26/9456 [pii]. DOI: 10.1523/JNEUROSCI.1460-11.2011 [PubMed: 21715610]
- Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, Bennett MVL, Berman JW. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. *Proc Nat Acad Sci USA*. 2007; 104:3438–3443. DOI: 10.1073/pnas.0611699104 [PubMed: 17360663]
- Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM. Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization. *J Neurochem*. 2010; 115:885–896. DOI: 10.1111/j.1471-4159.2010.06968.x [PubMed: 20796175]
- Fields J, Dumaop W, Eleuteri S, Campos S, Serger E, Trejo M, Kosberg K, Adame A, Spencer B, Rockenstein E, He JJ, Masliah E. HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders. *J Neurosci*. 2015; 35:1921–1938. DOI: 10.1523/JNEUROSCI.3207-14.2015 [PubMed: 25653352]
- Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, Trejo M, Adame A, Spencer B, Rockenstein E, Murphy AN, Ellis RJ, Letendre S, Grant I, Masliah E. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. *Neurobiol Dis*. 2016; 86:154–169. DOI: 10.1016/j.nbd.2015.11.015 [PubMed: 26611103]
- Gadaleta MN, Cormio A, Pesce V, Lezza AM, Cantatore P. Aging and mitochondria. *Biochimie*. 1998; 80:863–870. [PubMed: 9893945]
- Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. *J Neurosci*. 2002; 22:4015–4024. 20026351. [PubMed: 12019321]
- Garden GA, Guo W, Jayadev S, Tun C, Balcaitis S, Choi J, Montine TJ, Moller T, Morrison RS. HIV associated neurodegeneration requires p53 in neurons and microglia. *FASEB J*. 2004; 18:1141–1143. [PubMed: 15155568]
- Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. *Cell Death Differ*. 2006; 13:1423–1433. DOI: 10.1038/sj.cdd.4401950 [PubMed: 16676004]
- Grimaldi M, Denizot M, Espert L, Robert-Hebmann V, Biard-Piechaczyk M. Mitochondria-dependent apoptosis in T-cell homeostasis. *Curr Opin Investig Drugs*. 2005; 6:1095–1102.
- Haughey NJ, Mattson MP. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. *J Acquir Immune Defic Syndr*. 2002; 31(Suppl 2):S55–61. [PubMed: 12394783]
- Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. *J Neurochem*. 2001; 78:457–467. [PubMed: 11483648]

- Hoke A, Morris M, Haughey NJ. GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. *J Peripher Nerv Syst.* 2009; 14:27–35. DOI: 10.1111/j.1529-8027.2009.00203.x [PubMed: 19335537]
- Hu XT. HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions. *Curr Drug Targets.* 2016; 17:4–14. [PubMed: 26028040]
- Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, Male D, Everall I. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. *J Neurovirol.* 2000; 6:145–155. [PubMed: 10822328]
- Hui L, Chen X, Haughey NJ, Geiger JD. Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. *ASN Neuro.* 2012; 4:243–252. e00091 [pii] AN20120017 [pii]. DOI: 10.1042/AN20120017 [PubMed: 22591512]
- Itoh K, Nakamura K, Iijima M, Sesaki H. Mitochondrial dynamics in neurodegeneration. *Trends Cell Biol.* 2013; 23:64–71. DOI: 10.1016/j.tcb.2012.10.006 [PubMed: 23159640]
- Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Daugas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP, Kroemer G. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. *J Exp Med.* 2000; 191:33–46. [PubMed: 10620603]
- Janssen RS, Cornblath DR, Epstein LG, McArthur J, Price RW. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. *Neurology.* 1989; 39:119–122. [PubMed: 2642609]
- Joshi DC, Bakowska JC. Determination of mitochondrial membrane potential and reactive oxygen species in live rat cortical neurons. *J Vis Exp.* 2011; doi: 10.3791/2704
- Kanmogne GD, Primeaux C, Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. *J Neuropathol Exp Neurol.* 2005; 64:498–505. [PubMed: 15977641]
- Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature.* 2001; 410:988–994. [PubMed: 11309629]
- Kim HJ, Martemyanov KA, Thayer SA. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. *J Neurosci.* 2008; 28:12604–12613. DOI: 10.1523/JNEUROSCI.2958-08.2008 [PubMed: 19036954]
- Krogh KA, Wydeven N, Wickman K, Thayer SA. HIV-1 protein Tat produces biphasic changes in NMDA-evoked increases in intracellular Ca²⁺ concentration via activation of Src kinase and nitric oxide signaling pathways. *J Neurochem.* 2014; 130:642–656. DOI: 10.1111/jnc.12724 [PubMed: 24666322]
- Kruman II, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. *Exp Neurol.* 1998; 154:276–288. DOI: 10.1006/exnr.1998.6958 [PubMed: 9878167]
- Laughlin SB, de Ruyter van Steveninck RR, Anderson JC. The metabolic cost of neural information. *Nat Neurosci.* 1998; 1:36–41. DOI: 10.1038/236 [PubMed: 10195106]
- Lecoeur H, Borgne-Sanchez A, Chaloin O, El-Khoury R, Brabant M, Langonne A, Porceddu M, Briere JJ, Buron N, Rebouillat D, Pechoux C, Deniaud A, Brenner C, Briand JP, Muller S, Rustin P, Jacotot E. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. *Cell Death Dis.* 2012; 3:e282.doi: 10.1038/cddis.2012.21 [PubMed: 22419111]
- Lehmann HC, Chen W, Borzan J, Mankowski JL, Hoke A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. *Ann Neurol.* 2011; 69:100–110. DOI: 10.1002/ana.22150 [PubMed: 21280080]
- Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A. NMDA receptor activation by HIV-Tat protein is clade dependent. *J Neurosci.* 2008; 28:12190–12198. DOI: 10.1523/JNEUROSCI.3019-08.2008 [PubMed: 19020013]
- Li Y, Zhou M, Hu Q, Bai XC, Huang W, Scheres SH, Shi Y. Mechanistic insights into caspase-9 activation by the structure of the apoptosome holoenzyme. *Proc Natl Acad Sci U S A.* 2017; 114:1542–1547. DOI: 10.1073/pnas.1620626114 [PubMed: 28143931]

- Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. *Cell*. 2004; 119:873–887. DOI: 10.1016/j.cell.2004.11.003 [PubMed: 15607982]
- Lipton SA, Sucher NJ, Kaiser PK, Dreyer EB. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. *Neuron*. 1991; 7:111–118. [PubMed: 1676893]
- Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell*. 1996; 86:147–157. [PubMed: 8689682]
- Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, Moir RD, Nath A, He JJ. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. *Nat Med*. 2000; 6:1380–1387. DOI: 10.1038/82199 [PubMed: 11100124]
- Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. *J Neuropathol Exp Neurol*. 2010; 69:801–816. DOI: 10.1097/NEN.0b013e3181e8c96f [PubMed: 20613638]
- Marosi K, Mattson MP. BDNF mediates adaptive brain and body responses to energetic challenges. *Trends in Endocrinology & Metabolism*. 2014; 25:89–98. doi: <http://dx.doi.org/10.1016/j.tem.2013.10.006>. [PubMed: 24361004]
- Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. *Ann Neurol*. 1997; 42:963–972. [PubMed: 9403489]
- Matarrese P, Cauda R, Malorni W. Activation-associated mitochondrial hyperpolarization hijacks T cells toward an apoptosis-sensitized phenotype. *Cell Death Differ*. 2003; 10:609–611. DOI: 10.1038/sj.cdd.4401212 [PubMed: 12728259]
- Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. *Neuron*. 2008; 60:748–766. DOI: 10.1016/j.neuron.2008.10.010 [PubMed: 19081372]
- Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. *Cell Death Differ*. 2005; 12(Suppl 1): 893–904. DOI: 10.1038/sj.cdd.4401577 [PubMed: 15761472]
- Mehta A, Haber JE. Sources of DNA double-strand breaks and models of recombinational DNA repair. *Cold Spring Harb Perspect Biol*. 2014; 6:a016428.doi: 10.1101/cshperspect.a016428 [PubMed: 25104768]
- Merrill RA, Dagda RK, Dickey AS, Cribbs JT, Green SH, Usachev YM, Strack S. Mechanism of neuroprotective mitochondrial remodeling by PKA/AKAP1. *PLoS Biol*. 2011; 9:e1000612.doi: 10.1371/journal.pbio.1000612 [PubMed: 21526220]
- Meucci O, Miller RJ. gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta1. *J Neurosci*. 1996; 16:4080–4088. [PubMed: 8753870]
- Moran LM, Booze RM, Webb KM, Mactutus CF. Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. *Exp Neurol*. 2013; 239:139–147. DOI: 10.1016/j.expneurol.2012.10.008 [PubMed: 23063600]
- Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. *Ann Neurol*. 2000; 47:186–194. [PubMed: 10665489]
- Nath S, Bachani M, Harshavardhana D, Steiner JP. Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. *J Neurovirol*. 2012; 18:445–455. DOI: 10.1007/s13365-012-0122-1 [PubMed: 22886603]
- Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. *Lancet Neurol*. 2014; 13:1139–1151. DOI: 10.1016/S1474-4422(14)70137-1 [PubMed: 25316020]
- Norman JP, Perry SW, Kasischke KA, Volsky DJ, Gelbard HA. HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons. *J Immunol*. 2007; 178:869–876. [PubMed: 17202348]

- Norman JP, Perry SW, Reynolds HM, Kiebal M, De Mesy Bentley KL, Trejo M, Volsky DJ, Maggirwar SB, Dewhurst S, Masliah E, Gelbard HA. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. *PLoS One*. 2008; 3:e3731.doi: 10.1371/journal.pone.0003731 [PubMed: 19009018]
- Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA. Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. *Exp Neurol*. 2007; 204:29–38. DOI: 10.1016/j.expneurol.2006.09.010 [PubMed: 17069802]
- Pandey V, Bolsover SR. Immediate and neurotoxic effects of HIV protein gp120 act through CXCR4 receptor. *Biochem Biophys Res Commun*. 2000; 274:212–215. DOI: 10.1006/bbrc.2000.3113 [PubMed: 10903920]
- Pehar M, Cassina P, Vargas MR, Xie Y, Beckman JS, Massa SM, Longo FM, Barbeito L. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. *Eur J Neurosci*. 2006; 24:1575–1580. DOI: 10.1111/j.1460-9568.2006.05040.x [PubMed: 17004921]
- Perry SW, Norman JP, Litzburg A, Zhang D, Dewhurst S, Gelbard HA. HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis. *J Immunol*. 2005; 174:4333–4344. [PubMed: 15778398]
- Pocernich CB, Sultana R, Mohammad-Abdul H, Nath A, Butterfield DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. *Brain Res Brain Res Rev*. 2005; 50:14–26. DOI: 10.1016/j.brainresrev.2005.04.002 [PubMed: 15890409]
- Polazzi E, Levi G, Minghetti L. Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. *J Neuropathol Exp Neurol*. 1999; 58:825–831. [PubMed: 10446807]
- Price TO, Ercal N, Nakaoke R, Banks WA. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. *Brain Res*. 2005; 1045:57–63. DOI: 10.1016/j.brainres.2005.03.031 [PubMed: 15910762]
- Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. *Exp Neurol*. 2006; 201:193–202. DOI: 10.1016/j.expneurol.2006.03.030 [PubMed: 16750528]
- Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. *Curr Alzheimer Res*. 2011; 8:393–409. [PubMed: 21470101]
- Rozzi SJ, Borelli G, Ryan K, Steiner JP, Reglodi D, Mocchetti I, Avdoshina V. PACAP27 is protective against tat-induced neurotoxicity. *J Mol Neurosci*. 2014; 54:485–493. DOI: 10.1007/s12031-014-0273-z [PubMed: 24696163]
- Sanchez AB, Varano GP, de Rozieres CM, Maung R, Catalan IC, Dowling CC, Sejbuk NE, Hoefer MM, Kaul M. Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage. *Antimicrob Agents Chemother*. 2015; 60:168–179. DOI: 10.1128/AAC.01632-15 [PubMed: 26482305]
- Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC. HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. *Nat Rev Neurol*. 2016; 12:234–248. DOI: 10.1038/nrneurol.2016.27 [PubMed: 26965674]
- Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccaldi AG, Littman DR, Fenyo EM, Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. *Nat Med*. 1997; 3:1259–1265. [PubMed: 9359702]
- Schuler W, Wecker K, de Rocquigny H, Baudat Y, Sire J, Roques BP. NMR structure of the (52–96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. *J Mol Biol*. 1999; 285:2105–2117. DOI: 10.1006/jmbi.1998.2381 [PubMed: 9925788]
- Self RL, Mulholland PJ, Nath A, Harris BR, Prendergast MA. The human immunodeficiency virus type-1 transcription factor Tat produces elevations in intracellular Ca²⁺ that require function of

an N-methyl-D-aspartate receptor polyamine-sensitive site. *Brain Res.* 2004; 995:39–45. [PubMed: 14644469]

Sheng ZH. Mitochondrial trafficking and anchoring in neurons: New insight and implications. *J Cell Biol.* 2014; 204:1087–1098. DOI: 10.1083/jcb.201312123 [PubMed: 24687278]

Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, Nath A, Hauser KF. Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. *J Neurovirol.* 2004; 10:141–151. [PubMed: 15204919]

Singh KK, Park KJ, Hong EJ, Kramer BM, Greenberg ME, Kaplan DR, Miller FD. Developmental axon pruning mediated by BDNF-p75NTR-dependent axon degeneration. *Nat Neurosci.* 2008; 11:649–658. nn.2114 [pii]. DOI: 10.1038/nn.2114 [PubMed: 18382462]

Stauber RH, Pavlakis GN. Intracellular trafficking and interactions of the HIV-1 Tat protein. *Virology.* 1998; 252:126–136. [PubMed: 9875323]

Stevens PR, Gawryluk JW, Hui L, Chen X, Geiger JD. Creatine protects against mitochondrial dysfunction associated with HIV-1 Tat-induced neuronal injury. *Curr HIV Res.* 2014; 12:378–387. [PubMed: 25613139]

Stojanovski D, Koutsopoulos OS, Okamoto K, Ryan MT. Levels of human Fis1 at the mitochondrial outer membrane regulate mitochondrial morphology. *J Cell Sci.* 2004; 117:1201–1210. DOI: 10.1242/jcs.01058 [PubMed: 14996942]

Su B, Ji YS, Sun XL, Liu XH, Chen ZY. Brain-derived neurotrophic factor (BDNF)-induced mitochondrial motility arrest and presynaptic docking contribute to BDNF-enhanced synaptic transmission. *J Biol Chem.* 2014; 289:1213–1226. DOI: 10.1074/jbc.M113.526129 [PubMed: 24302729]

Tardieu M, Hery C, Peudenier S, Boespflug O, Montagnier L. Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion. *Ann Neurol.* 1992; 32:11–17. DOI: 10.1002/ana.410320104 [PubMed: 1303631]

Tiede LM, Cook EA, Morsey B, Fox HS. Oxygen matters: tissue culture oxygen levels affect mitochondrial function and structure as well as responses to HIV viroproteins. *Cell Death Dis.* 2011; 2:e246.doi: 10.1038/cddis.2011.128 [PubMed: 22190005]

Todorova V, Blokland A. Mitochondria and Synaptic Plasticity in the Mature and Aging Nervous System. *Curr Neuropharmacol.* 2017; 15:166–173. [PubMed: 27075203]

Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. *Nature.* 1994; 367:188–193. [PubMed: 8114918]

Turchan J, Anderson C, Hauser KF, Sun Q, Zhang J, Liu Y, Wise PM, Kruman I, Maragos W, Mattson MP, Booze R, Nath A. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. *BMC Neurosci.* 2001; 2:3. [PubMed: 11252157]

van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. *Cold Spring Harb Perspect Biol.* 2013; 5:doi: 10.1101/cshperspect.a011072

Villeneuve LM, Purnell PR, Stauch KL, Callen SE, Buch SJ, Fox HS. HIV-1 transgenic rats display mitochondrial abnormalities consistent with abnormal energy generation and distribution. *J Neurovirol.* 2016; 22:564–574. DOI: 10.1007/s13365-016-0424-9 [PubMed: 26843384]

Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR. Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. *J Neuroinflammation.* 2004; 1:8.doi: 10.1186/1742-2094-1-8 [PubMed: 15285794]

Westermann B. Mitochondrial fusion and fission in cell life and death. *Nat Rev Mol Cell Biol.* 2010; 11:872–884. DOI: 10.1038/nrm3013 [PubMed: 21102612]

Williams KS, Killebrew DA, Clary GP, Meeker RB. Opposing Effects of NGF and proNGF on HIV Induced Macrophage Activation. *J Neuroimmune Pharmacol.* 2016; 11:98–120. DOI: 10.1007/s11481-015-9631-z [PubMed: 26420421]

Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. *Nat Neurosci.* 2005; 8:1069–1077. nn1510 [pii]. DOI: 10.1038/nn1510 [PubMed: 16025106]

- Xu H, Bae M, Tovar-y-Romo LB, Patel N, Bandaru VV, Pomerantz D, Steiner JP, Haughey NJ. The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. *J Neurosci*. 2011; 31:17074–17090. DOI: 10.1523/JNEUROSCI.4072-11.2011 [PubMed: 22114277]
- Yang J, Harte-Hargrove LC, Siao CJ, Marinic T, Clarke R, Ma Q, Jing D, Lafrancois JJ, Bath KG, Mark W, Ballon D, Lee FS, Scharfman HE, Hempstead BL. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. *Cell Rep*. 2014; 7:796–806. DOI: 10.1016/j.celrep.2014.03.040 [PubMed: 24746813]
- Yoon YS, Yoon DS, Lim IK, Yoon SH, Chung HY, Rojo M, Malka F, Jou MJ, Martinou JC, Yoon G. Formation of elongated giant mitochondria in DFO-induced cellular senescence: involvement of enhanced fusion process through modulation of Fis1. *J Cell Physiol*. 2006; 209:468–480. DOI: 10.1002/jcp.20753 [PubMed: 16883569]
- Zhang Y, Wang M, Li H, Zhang H, Shi Y, Wei F, Liu D, Liu K, Chen D. Accumulation of nuclear and mitochondrial DNA damage in the frontal cortex cells of patients with HIV-associated neurocognitive disorders. *Brain Res*. 2012; 1458:1–11. DOI: 10.1016/j.brainres.2012.04.001 [PubMed: 22554480]

Figure 1.

Neuronal mitochondria in HAND display disrupted cristae. Cortical sections from HIV+ subjects with no cognitive alterations and HAND subjects were analyzed by transmission electron microscopy (TEM) as previously described (Avdoshina et al. 2016a) to visualize mitochondria. Please note that mitochondria (arrows) in HAND exhibit loss of well-defined cristae (bar = 1 μ m). Magnification 25,000X.

Figure 2.

Viral protein gp120 alters mitochondrial morphology. Mitochondrial morphology was visualized by TEM in cortical sections from wild type (WT) and gp120 transgenic (gp120-tg) mice. Note that mitochondria (arrows) in gp120-tg mice display broken cristae. Often, mitochondria in gp120-tg animals are abnormally elongated (bar =1 μ m).

Figure 3.

Tat rapidly increases $[Ca^{2+}]_i$ in a NMDA receptor independent manner. Cultured rat cortical neurons (DIV7) prepared as described previously (Avdoshina et al. 2016b) were exposed for up to 200 sec to recombinant Tat (100nM) or NMDA (100 μM) alone or in combination with the NMDA receptor antagonist MK801 (60μM). A and B: Representative Fluo-4 fluorescence images of cortical neurons captured before (baseline) and after application of Tat or NMDA in the presence of absence of MK801. C and D: Mean Fluo-4 fluorescence of A and B, respectively (n >20 cells). Note that addition of Tat resulted in a significant increase in $[Ca^{2+}]_i$, which was not prevented when the NMDA receptor antagonist MK801 was added concurrently. Neurons were responsive to NMDA, which caused a rapid and robust rise in $[Ca^{2+}]_i$, prevented by the concurrent administration of MK801 (B and D).